Literature DB >> 9523576

Expression, purification, and encephalitogenicity of recombinant human myelin oligodendrocyte glycoprotein.

J Bettadapura1, K K Menon, S Moritz, J Liu, C C Bernard.   

Abstract

Myelin oligodendrocyte glycoprotein (MOG), a putative autoantigen in multiple sclerosis (MS), is a quantitatively minor component of the CNS. In view of the difficulties associated with the purification of MOG from brain tissues, the extracellular domain of human MOG corresponding to the N-terminal 121 amino acids was expressed in Escherichia coli as a glutathione sulfotransferase fusion protein. The expressed protein was localized to inclusion bodies, and varying the growth parameters resulted in the solubilization of small amounts of GST-MOG that could be affinity purified on glutathione agarose columns. The fusion protein found in the inclusion bodies could be solubilized with urea. The solubilized fusion protein was cleaved with thrombin, and the extracellular domain was purified by CM Sephadex 50 chromatography to homogeneity. Injection of recombinant human MOG into different strains of mice resulted in the induction of an MS-like disease, characterized by severe neurological impairment and extensive CNS demyelinated lesions. Recombinant MOG produced in E. coli should prove to be useful as a highly purified biological reagent for immunological, pathological, functional, and structural studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523576     DOI: 10.1046/j.1471-4159.1998.70041593.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Quantitative and phenotypic analysis of bone marrow-derived cells in the intact and inflamed central nervous system.

Authors:  Martin A Short; Naomi Campanale; Sara Litwak; Claude C A Bernard
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

Review 2.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies.

Authors:  Rajiv W Jain; Amy K Dang; Steven M Kerfoot
Journal:  J Vis Exp       Date:  2016-10-27       Impact factor: 1.355

4.  Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation.

Authors:  Bryan Vander Lugt; Aly A Khan; Jason A Hackney; Smita Agrawal; Justin Lesch; Meijuan Zhou; Wyne P Lee; Summer Park; Min Xu; Jason DeVoss; Chauncey J Spooner; Cecile Chalouni; Lelia Delamarre; Ira Mellman; Harinder Singh
Journal:  Nat Immunol       Date:  2013-12-22       Impact factor: 25.606

5.  Critical role of activation induced cytidine deaminase in experimental autoimmune encephalomyelitis.

Authors:  Yonglian Sun; Ivan Peng; Kate Senger; Kajal Hamidzadeh; Mike Reichelt; Miriam Baca; Ronald Yeh; Maria N Lorenzo; Andrew Sebrell; Christopher Dela Cruz; Lucinda Tam; Racquel Corpuz; Jiansheng Wu; Tao Sai; Merone Roose-Girma; Søren Warming; Mercedesz Balazs; Lino C Gonzalez; Patrick Caplazi; Flavius Martin; Jason Devoss; Ali A Zarrin
Journal:  Autoimmunity       Date:  2013-01-18       Impact factor: 2.815

6.  Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis.

Authors:  Natalie L Payne; Guizhi Sun; Daniella Herszfeld; Pollyanna A Tat-Goh; Paul J Verma; Helena C Parkington; Harold A Coleman; Mary A Tonta; Christopher Siatskas; Claude C A Bernard
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

7.  Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.

Authors:  Lawrence Steinman
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

8.  Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis.

Authors:  Conan K Wang; Christian W Gruber; Maša Cemazar; Christopher Siatskas; Prascilla Tagore; Natalie Payne; Guizhi Sun; Shunhe Wang; Claude C Bernard; David J Craik
Journal:  ACS Chem Biol       Date:  2013-11-07       Impact factor: 5.100

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.